Is obesity a risk factor for melanoma?
Melanoma
Obesity
Risk factor
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
22 Feb 2023
22 Feb 2023
Historique:
received:
09
08
2022
accepted:
18
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Are twofold: 1) to estimate the relationship between obesity (BMI ≥30) and the prevalence of melanoma in different US states and 2) to examine the possibility of defining a new risk group. This might enhance the possibility of detection, which in turn, might increase the survival rates of patients. A cohort Study, based on data at the US statewide level in 2011-2017, where the dependent variable (the annual new melanoma cases per 100,000 persons) is adjusted for age. Quadratic regression analysis. This model permits a non-monotonic variation of obesity with new melanoma cases adjusted for age, where the control variable is the level of UV radiation. Demonstrate a negative correlation between obesity and incidence of melanoma. This outcome is further corroborated for Caucasians. We should continue to establish primary prevention of melanoma by raising photo protection awareness and secondary prevention by promoting skin screening (by physician or self) among the entire population group in all BMI ranges. Advanced secondary melanoma prevention including noninvasive diagnosis strategies including total body photography, confocal microscopy, AI strategies should focus the high-risk sub group of Caucasians with BMI < 30.
Identifiants
pubmed: 36814240
doi: 10.1186/s12885-023-10560-8
pii: 10.1186/s12885-023-10560-8
pmc: PMC9944773
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2016 May 28;387(10034):2207-17
pubmed: 27045735
Arch Pathol Lab Med. 2011 Mar;135(3):342-6
pubmed: 21366458
J Okla State Med Assoc. 2016 Jul-Aug;109(7-8):311-316
pubmed: 27885301
Curr Oncol Rep. 2016 Sep;18(9):56
pubmed: 27475805
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S78-86
pubmed: 22018071
J Invest Dermatol. 1998 Aug;111(2):218-21
pubmed: 9699720
Br J Dermatol. 2017 Jul;177(1):134-140
pubmed: 28369739
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
Nutr Metab (Lond). 2015 Nov 25;12:50
pubmed: 26612998
Nat Rev Endocrinol. 2020 Jul;16(7):341-342
pubmed: 32327737
Int J Obes (Lond). 2020 Nov;44(11):2339-2342
pubmed: 32934319
Pathophysiology. 2017 Mar;24(1):31-37
pubmed: 28143686
Int J Epidemiol. 2020 Aug 1;49(4):1236-1245
pubmed: 32068838
Cancer Epidemiol. 2016 Feb;40:119-25
pubmed: 26707237
Eur J Cancer. 2013 Feb;49(3):642-57
pubmed: 23200191
Health Place. 2014 Mar;26:118-26
pubmed: 24434082
JAMA Netw Open. 2021 Mar 1;4(3):e213520
pubmed: 33779745
J Invest Dermatol. 2019 Jan;139(1):25-30
pubmed: 30482597
Dermatol Surg. 2019 Jun;45(6):791-801
pubmed: 30614836
Cancer Treat Res. 2014;159:443-55
pubmed: 24114495
Eur J Cancer. 2022 Jul;170:256-284
pubmed: 35623961
J Am Acad Dermatol. 2022 Mar;86(3):515-524
pubmed: 34915056